Qinlock (ripretinib) is the First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors
19 Maggio 2020
The FDA has approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a
